膀胱癌免疫治疗中中枢训练免疫的研究

IF 48.8 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2025-07-03 DOI:10.1016/j.ccell.2025.06.010

Julia Chronopoulos, Maria Crespo, Triantafyllos Chavakis

引用次数: 0

摘要

《免疫》和《癌细胞》杂志上的两篇文章描述了单独使用卡介苗（BCG）或与另一种训练免疫激动剂(TRIM) β-葡聚糖联合使用膀胱癌的免疫治疗涉及骨髓（BM）造血的重编程。这些发现为脑卒中介导的TRIM治疗癌症的潜力提供了额外的证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Central trained immunity in the context of bladder cancer immunotherapy

Two articles in Immunity and Cancer Cell describe that bladder cancer immunotherapy with Bacillus Calmette-Guerin (BCG) alone or in combination with β-glucan, another agonist of trained immunity (TRIM), involves reprogramming of bone marrow (BM) hematopoiesis. These findings provide additional evidence of the therapeutic potential of BM-mediated TRIM against cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.